ストックスクリーナーアプリを入手
20.26
0.10%
-0.02
前日終値:
$20.28
開ける：
$20.21
24時間の取引高:
2.36M
Relative Volume:
0.93
時価総額：
$4.81B
収益：
$382.81M
当期純損益:
$68.13M
株価収益率:
72.36
EPS:
0.28
ネットキャッシュフロー:
$78.82M
1週間 パフォーマンス:
+2.32%
1か月 パフォーマンス:
+31.22%
6か月 パフォーマンス:
+4.51%
1年 パフォーマンス:
+206.97%
1日の値動き範囲:
$19.72
$20.63
1週間の範囲:
$19.45
$20.70
52週間の値動き範囲:
$5.895
$23.64
Adma Biologics Inc Stock (ADMA) Company Profile
ADMA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
20.26 | 4.81B | 382.81M | 68.13M | 78.82M | 0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-07-19 | 再開されました | Raymond James | Strong Buy |
| 2022-10-13 | 開始されました | Mizuho | Buy |
| 2021-11-11 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-04 | 開始されました | Jefferies | Buy |
| 2019-04-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-07 | 再開されました | H.C. Wainwright | Buy |
| 2017-12-11 | 繰り返されました | Maxim Group | Buy |
| 2017-11-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | アップグレード | Maxim Group | Hold → Buy |
| 2016-08-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2016-07-25 | 繰り返されました | Maxim Group | Buy |
| 2015-05-13 | 繰り返されました | Maxim Group | Buy |
| 2014-12-08 | 開始されました | Oppenheimer | Outperform |
| 2014-12-01 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Adma Biologics Inc (ADMA) 最新ニュース
Adma Biologics (ADMA) Stock Moves -0.15%: What You Should Know - Nasdaq
How IBD Stock Of The Day ADMA Biologics Shrugged Off Accounting Debacle For A Bullish Comeback - MSN
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy? - Zacks Investment Research
Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains? - MSN
Adma Biologics CEO Adam Grossman sells $397,320 in stock By Investing.com - Investing.com Australia
Adma Biologics CEO Adam Grossman sells $397,320 in stock - Investing.com
Here is What to Know Beyond Why ADMA Biologics Inc (ADMA) is a Trending Stock - Yahoo Finance
ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential - Seeking Alpha
Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know - Yahoo Finance
ADMA Stock Builds A Base As Profits Continue To Soar - MSN
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why - Yahoo Finance
Pulse of the Market: Wednesday’s 10 Top Performers - Insider Monkey
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus.com
Why ADMA Biologics Inc. (ADMA) Went Up On Wednesday? - Yahoo Finance
Why Adma Biologics (ADMA) Outpaced the Stock Market Today - MSN
Will ADMA Biologics Stock Continue Its Momentum in 2025? - Yahoo Finance
Should You Invest in Adma Biologics (ADMA) Based on Bullish Wall Street Views? - Yahoo Finance
Adma Biologics (ADMA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
What's Driving the Market Sentiment Around ADMA Biologics? - Benzinga
Commit To Buy ADMA Biologics At $10, Earn 14% Using Options - Nasdaq
Bank of New York Mellon Corp Has $26.09 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Mutual of America Capital Management LLC Has $614,000 Stake in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook - MSN
Lost Money on ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Lisanti Capital Growth LLC Sells 59,565 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Mizuho lifts ADMA Biologics price target to $32, maintains Outperform - Investing.com
How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85% - MSN
ADMA Biologics Stock Climbs Amid Strong Earnings - TipRanks
ADMA Biologics (NASDAQ:ADMA) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Buy Rating Affirmed for ADMA Biologics Amid Transition to New Auditor and Growth Prospects - TipRanks
ADMA Biologics Earnings Call Highlights Strong Growth - TipRanks
ADMA Biologics Inc earnings beat by $0.31, revenue topped estimates - Investing.com Australia
BREAKING: Block & Leviton Investigating ADMA Biologics, - GlobeNewswire
BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed - EIN News
ADMA Biologics slips as 10-K delay overshadows earnings beat - MSN
ADMA Biologics stock slips on 10-K delay (ADMA:NASDAQ) - Seeking Alpha
ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2024 Earnings Call Transcript - Insider Monkey
ADMA Biologics Reports Strong 2024 Financial Performance - MSN
ADMA Biologics Inc (ADMA) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
ADMA Biologics Inc (ADMA) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Earnings call transcript: ADMA Biologics Q4 2024 beats EPS forecast - Investing.com India
ADMA Biologics Delays 10-K Filing Amid Auditor Change - TipRanks
Adma Biologics Inc (ADMA) 財務データ
収益
当期純利益
現金流量
EPS
Adma Biologics Inc (ADMA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Mar 19 '25 |
Sale |
18.92 |
21,000 |
397,320 |
2,061,850 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):